ELAC2 Antikörper
-
- Target Alle ELAC2 Antikörper anzeigen
- ELAC2 (ElaC Homolog 2 (ELAC2))
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser ELAC2 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA
- Produktmerkmale
- Polyclonal Antibody
- Aufreinigung
- Affinity purification
- Immunogen
- Recombinant protein of human ELAC2
- Isotyp
- IgG
- Top Product
- Discover our top product ELAC2 Primärantikörper
-
-
- Applikationshinweise
- WB 1:500-1:2000
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.7 mg/mL
- Buffer
- PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
- Target
- ELAC2 (ElaC Homolog 2 (ELAC2))
- Andere Bezeichnung
- ELAC2 (ELAC2 Produkte)
- Hintergrund
- The protein encoded by this gene has a C-terminal domain with tRNA 3′, processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene.
- Molekulargewicht
- 92 kDa
- UniProt
- Q9BQ52
-